Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

被引：11

作者：

Jain, Nitin ^{[1
]}

Thompson, Philip A. ^{[1
]}

Burger, Jan A. ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Borthakur, Gautam ^{[2
]}

Bose, Prithviraj ^{[1
]}

Estrov, Zeev E. ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Takahashi, Koichi ^{[1
]}

Garg, Naveen ^{[3
]}

Wang, Xuemei ^{[4
]}

Kanagal-Shamanna, Rashmi ^{[5
]}

Patel, Keyur ^{[5
]}

Lopez, Wanda ^{[1
]}

Ayala, Ana ^{[1
]}

Plunkett, William ^{[6
]}

Gandhi, Varsha ^{[6
]}

Kantarjian, Hagop M. ^{[1
]}

O'Brien, Susan M. ^{[7
]}

Keating, Michael J. ^{[1
]}

Wierda, William G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页数：4

共 50 条

[21] Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
Visentin, Andrea
Mauro, Francesca Romana
Catania, Gioachino
Fresa, Alberto
Vitale, Candida
Sanna, Alessandro
Mattiello, Veronica
Cibien, Francesca
Sportoletti, Paolo
Gentile, Massimo
Rigolin, Gian Matteo
Quaglia, Francesca Maria
Murru, Roberta
Gozzetti, Alessandro
Molica, Stefano
Marchetti, Monia
Pravato, Stefano
Angotzi, Francesco
Cellini, Alessandro
Scarfo, Lydia
Reda, Gianluigi
Coscia, Marta
Laurenti, Luca
Ghia, Paolo
Foa, Robin
Cuneo, Antonio
Trentin, Livio
FRONTIERS IN ONCOLOGY, 2022, 12
[22] Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Yi Miao
Yeqin Sha
Yi Xia
Shuchao Qin
Rui Jiang
Luomengjia Dai
Hui Shen
Tonglu Qiu
Wei Wu
Jingyan Qiu
Yilian Yang
Chongyang Ding
Yujie Wu
Lei Fan
Wei Xu
Jianyong Li
Huayuan Zhu
Blood Cancer Journal, 13
[23] Patients with TP53 Disruption and IGHV Mutated Status Show Indolent Clinical Course: A Study on 1,327 Treatment-Naive CLL Cases
Jeromin, Sabine
Haferlach, Claudia
Dicker, Frank
Haferlach, Torsten
Kern, Wolfgang
BLOOD, 2016, 128 (22)
[24] Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
Slot, Matilde
Niemann, Carsten Utoft
Ehlers, Lars Holger
Rotbain, Emelie Curovic
BLOOD ADVANCES, 2023, 7 (15) : 4186 - 4196
[25] Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations
Sivina, Mariela
Kim, Ekaterina
Wierda, William G.
Ferrajoli, Alessandra
Jain, Nitin
Thompson, Philip
Kantarjian, Hagop
Keating, Michael
Burger, Jan A.
BLOOD, 2021, 138 (24) : 2589 - 2592
[26] Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
Bomben, Riccardo
Rossi, Francesca Maria
Vit, Filippo
Bittolo, Tamara
Zucchetto, Antonella
Papotti, Robel
Tissino, Erika
Pozzo, Federico
Degan, Massimo
Polesel, Jerry
Bulian, Pietro
Marasca, Roberto
Reda, Gianluigi
Laurenti, Luca
Olivieri, Jacopo
Chiarenza, Annalisa
Laureana, Roberta
Postorino, Massimiliano
Del Principe, Maria Ilaria
Cuneo, Antonio
Gentile, Massimo
Morabito, Fortunato
Fronza, Gilberto
Tafuri, Agostino
Zaja, Francesco
Foa, Robin
Di Raimondo, Francesco
Del Poeta, Giovanni
Gattei, Valter
LEUKEMIA, 2023, 37 (04) : 914 - 918
[27] Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
Riccardo Bomben
Francesca Maria Rossi
Filippo Vit
Tamara Bittolo
Antonella Zucchetto
Robel Papotti
Erika Tissino
Federico Pozzo
Massimo Degan
Jerry Polesel
Pietro Bulian
Roberto Marasca
Gianluigi Reda
Luca Laurenti
Jacopo Olivieri
Annalisa Chiarenza
Roberta Laureana
Massimiliano Postorino
Maria Ilaria Del Principe
Antonio Cuneo
Massimo Gentile
Fortunato Morabito
Gilberto Fronza
Agostino Tafuri
Francesco Zaja
Robin Foà
Francesco Di Raimondo
Giovanni Del Poeta
Valter Gattei
Leukemia, 2023, 37 : 914 - 918
[28] TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG
Zenz, Thorsten
Hoth, Patrick
Busch, Raymonde
Helfrich, Hanne
Winkler, Dirk
Buehler, Andreas
Patten, Nancy
Truong, Sim
Wu, Lin
Fingerle-Rowson, Guenther
Fischer, Kirsten
Fink, Anna-Maria
Jaeger, Ulrich
Boettcher, Sebastian
Kneba, Michael
Wenger, Michael K.
Mendila, Myriam
Hallek, Michael
Doehner, Hartmut
Stilgenbauer, Stephan
BLOOD, 2009, 114 (22) : 521 - 521
[29] Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study
Visentin, Andrea
Mauro, Francesca Romana
Cibien, Francesca
Vitale, Candida
Reda, Gianluigi
Fresa, Alberto
Ciolli, Stefania
Pietrasanta, Daniela
Marchetti, Monia
Murru, Roberta
Gentile, Massimo
Rigolin, Gian Matteo
Quaglia, Francesca Maria
Scarfo, Lydia
Sportoletti, Paolo
Pravato, Stefano
Piazza, Francesco
Coscia, Marta
Laurenti, Luca
Molica, Stefano
Foa, Robin
Cuneo, Antonio
Trentin, Livio
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E95 - E99
[30] TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
Del Giudice, Ilaria
Cafforio, Luciana
Cappelli, Luca Vincenzo
Ilari, Caterina
Raponi, Sara
De Propris, Maria Stefania
Mariglia, Paola
Mauro, Francesca Romana
Vignetti, Marco
Guarini, Anna
Foa, Robin
BLOOD, 2018, 132

← 1 2 3 4 5 →